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Abstract
Background: Anaplastic thyroid cancer (ATC) is one of the most aggressive malignancies in humans, often
demonstrating resistance to multimodal therapeutic approaches. The median survival of ATC patients after initial
diagnosis was reported to be < 6 months due to the rapid progression of disease by dissemination and/or invasion.
There have been several reports describing possible effective chemotherapies, but these studies might be biased by
the nature of retrospective accumulations of clinical experiences, and thus reliable data concerning the efficacies of
the treatment efforts are required.
Design: In 2009, we established the research organization Anaplastic Carcinoma Research Consortium Japan
(ATCCJ) to investigate this highly malignant disease. Using this nationwide organization, we conducted a
prospective clinical study to investigate the feasibility, safeness, and efficacy of chemotherapy with weekly paclitaxel
for ATC patients. This trial is registered on the clinical trials site of the University Hospital Medical Information
Network Clinical Trials Registry Web site (UMIN000008574). The study was started in 2012, and enrollment was
closed in March 2014 after accumulating 71 patients from 28 registered institutes. The follow-up data will be
available in April 2015.
Discussion: Important information concerning the management of this disease is expected to be revealed by this
study. The concept and design of the study are described herein.
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Background
The management of anaplastic thyroid cancer (ATC) is
often difficult because of its aggressive characteristics
and the acquisition of resistance to multimodal thera-
peutic approaches [1]. The rareness of ATC (it accounts
for 1 % –4 % of thyroid cancer cases) has resulted in a
lack of accurate information concerning the disease,
including the outcomes of treatment efforts [2]. Long-
term experiences from single institutes may suggest dif-
ferent strategies to manage this disease [3, 4], and an
analysis using a common database lacked information
concerning the treatment efforts [5].
We therefore established the Anaplastic Thyroid
Carcinoma Research Consortium of Japan (ATCCJ) in
2009 to accumulate the clinical data of ATC patients
throughout Japan and to construct an authentic large
database [6]. Precise data (including the clinical manifesta-
tions of the patients, the therapeutic methods used, and
the outcomes) were accumulated in January 2010 and are
updated annually to form the world’s largest database of
ATC cases — over 1,000 cases from 57 institutions as of
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January 2014 [7]. In an analysis of the ATCCJ data, the
6-month disease-specific survival rates of the ATC pa-
tients in the database with stage IVA, B, and C disease
were revealed to be 60 %, 45 %, and 19 %, respectively.
Age over 70 years, acute symptoms, leukocytosis, tumor
dia. > 5 cm, extrathyroidal invasion, and distant metastasis
were revealed to be significant poor-prognosis factors [8].
Survival after surgery was significantly better when cura-
tive resection was accomplished, or when the disease was
observed incidentally during pathological examination
after surgery [9]. Surgery, extra-beam radiotherapy and/or
chemotherapy may contribute to longer survival in some
ATC cases [8].
These findings are important in the choice and
creation of therapeutic strategies. However, the practical
methods of treatment for ATC are not yet settled,
because of the nature of the analyses using retrospective
data accumulation.
Conventional chemotherapeutic treatment for ATC
using doxorubicin or cisplatinum did not demonstrate a
significant effect. The results of several investigations
suggested that taxane might be a good candidate agent
for controlling the disease [2, 10–13]. Higashiyama et al.
reported that the weekly administration of paclitaxel
could be beneficial to extend the survival of patients
with stage IVB ATC, without causing severe adverse
effects [12]. However, there are no precise data regarding
which ATC patients could safely undergo chemotherapy,
or about the objective response rate to the chemother-
apy. The present nationwide prospective clinical study to
evaluate the feasibility of weekly paclitaxel administra-
tion was conducted with ATC patients at every stage
and conditions with the goal of determining the feasibil-
ity, safety, and efficacy of this protocol. The study entrée




This study was conducted to prospectively evaluate the
feasibility and the safety of weekly paclitaxel chemother-
apy for patients with ATC. The efficacy of the treatment
was evaluated in patients who had evaluable lesions.
Primary endpoints
For the evaluation of the chemotherapy’s feasibility and
safety, we assessed the relative dose intensity and the
occurrence of adverse events. The study committee
estimated that approx. 80 % of the intended-to-treat pa-
tients would complete the initial course treatment with
the intended dose. We also evaluated the overall response
rate, time to failure, type of recurrence, and overall
survival in the patients with evaluable lesions.
Study design
The study was a multicenter, nonrandomized, open-label,
single-arm Phase II study.
Eligibility
Inclusion criteria
Patients with a pathologically proven diagnosis of anaplas-
tic thyroid cancer aged ≥20 years were eligible for the
study if they met the following criteria: Eastern Coopera-
tive Oncology Group (ECOG) performance status of 0 to
2, and adequate bone marrow, hepatic, and renal function.
The existence of a Response Evaluation Criteria in Solid
Tumors (RECIST) [14]-defined target lesion was not ne-
cessary for entry.
Exclusion criteria
Major exclusion criteria included previous chemotherapy
or radiation therapy for the present illness; suspicion of
interstitial pneumonia or pulmonary fibrosis by chest
radiograph; brain metastasis with one or more symp-
toms; the presence of an active peptic ulcer; the presence
of another active malignancy; history of severe drug al-
lergy; history of hypersensitivity to polyoxyethylated or
hydrogenated castor oil; hypersensitivity to alcohol.
Ethics and IRB approval
The study protocol was initially approved by the Institu-
tional Review Board (IRB) of the Osaka City University
Medical School in March 2012 (#2248). The study was then
approved by the IRB at each of the participating institutions
(Table 1), and was performed in accord with the Declar-
ation of Helsinki and Good Clinical Practice Guidelines.
Written informed consent was obtained from all patients
before study entry. This trial is registered on the clinical tri-
als website of the University Hospital Medical Information
Network Clinical Trials Registry (UMIN000008574).
Study protocol
The enrolled patients received intravenous chemotherapy
with weekly paclitaxel (80 mg/m2, once every week). One
course consisted of three administrations. At least one
course of the therapy was necessary. Therapy was contin-
ued when it was available and the patient’s physician con-
sidered it to be appropriate. The dose was reduced to
30 mg/m2 when concomitant extra-beam radiation was
conducted.
Due to the highly aggressive nature of ATC, a delay in
initiating the treatment may result in a critical deterioration
of the patient. Therefore, after obtaining the approval of the
protocol by each IRB, we asked for institutional registration
before each patient’s initial appearance and preparation for
acceptance. The protocol treatment was then allowed to be
initiated as soon as the patient’s physician had obtained the
patient’s consent for entry, upon the pathological diagnosis
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at the institution. The final pathological diagnosis of ATC
was confirmed by a central review by pathologists specializ-
ing in thyroid tumors, before the data analysis.
Assessment
Physical examinations and laboratory tests were performed
at baseline and repeated every week. Tumor assessments
were performed at baseline and every 3 weeks using the
RECIST criteria. Response (complete response/partial re-
sponse) had to be confirmed more than 3 weeks after it
was first noted. Adverse events were reported and graded
according to CTCAE v4.0 [National Cancer Institute 2009
Common Terminology Criteria for Adverse Events, version
4.0. Bethesda, MD; U.S. National Cancer Institute].
Statistical analysis of the responses to therapy
In the present study, the sample size was estimated as
described below to evaluate the possible survival benefit.
However, ATC is a rare disease and has an extremely
short survival period. Moreover, no reliable survival data
to refer to have been reported. The meaning of the
present findings should thus be evaluated carefully, even
though an estimated survival benefit was not observed.
The median survival times (MSTs) obtained with a con-
ventional therapeutic strategy and with the study proto-
col were estimated as 6 and 12 months, respectively.
The study entry period was 24 months and the observa-
tion period was 12 months, with a type I error (α) level
of 0.05 % and type II error (β) level of 0.20. The neces-
sary sample size was calculated as 41. Initially, we set 50
patients as a target size, expecting a 20 % drop-out rate.
The protocol was modified in August 2013 to include as
many patients as became available until the study period
closed, because a higher rate of pathology-based mis-
diagnoses was reported in another study compared to
what we estimated [15]. The overall survival curve will
be made by the Kaplan-Meier method.
Discussion
The initial proposal of this prospective clinical study was
made in 2011 at the annual assembly of the ATCCJ. The
initial draft was drawn soon after that by a primary in-
vestigator, and it was discussed and refined by a pro-
spective clinical study committee of the ATCCJ. The
study was open with the approval of the Ethics Commit-
tee of the Osaka City University Medical School in
March 2012. The progress of the study is summarized in
Fig. 1. The initial patient was enrolled in April 2012, and
a total of 71 patients had been enrolled in the study as
of the end of March 2014, when the enrollment period
was closed. Twenty-eight institutions from around Japan
had participated by the end of the enrollment period
(Table 1). No severe adverse event to terminate the
present study has been reported as of this writing, and
an adequate number of patients for an analysis of the
feasibility of the protocol was estimated to be enrolled.
The weekly administration of paclitaxel was chosen in
the present study because of its high feasibility rate in
elderly patients with other malignancies, its widespread
use in Japan, its low rate of adverse events compared to
other ATC treatments, its ability to be used as an induc-
tion therapy, and the capability for concordant irradi-
ation therapy (if needed), in addition to the high efficacy
of paclitaxel demonstrated in the initial paper [12].
Many combination therapies have been introduced
based on the weekly paclitaxel regimen to treat malig-
nancies of other organs, and future studies of the
addition of other anticancer agents to this simple regi-
men are possible.
During the preparation of this manuscript, the world’s
first prospective study targeting patients with ATC was
published by Sosa et al. [15]. That study was conducted
Table 1 The registered institutions
Institution
1. Osaka City University Hospital, Osaka
2. Kuma Hospital, Kobe
3. Kanaji Hospital, Tokyo
4. Ito Hospital, Tokyo
5. Shinshu University Hospital, Nagano
6. Cancer Institute Hospital, Tokyo
7. Nagasaki University Hospital, Nagasaki
8. Kanagawa Cancer Center, Kanagawa
9. Tsukuba University Hospital, Ibaraki
10. Fukushima Medical University Hospital, Fukushima
11. Nagasaki Medical Center Hospital, Nagasaki
12. Tohoku University Hospital, Sendai
13. Noguchi Hospital, Beppu
14. Aichi Cancer Center Hospital, Nagoya
15. International University of Health and Welfare, Mita Hospital, Tokyo
16. Ida Municipal Hospital, Nagano
17. Mito National Medical Center, Ibaraki
18. Sumitomo Hospital, Osaka
19. Tokyo Medical University Hachioji Medical Center, Tokyo
20. Narita Red Cross Hospital, Chiba
21. National Cancer Center Hospital, Tokyo
22. Uchimaru Hospital, Morioka
23. Iwate Medical University Hospital, Morioka
24. Yokohama City University Hospital, Kanagawa
25. Yokohama City University Medical Center, Kanagawa
26. Kanazawa University Hospital, Ishikawa
27. Nippon Medical School Hospital, Tokyo
28. Kanazawa Medical University Hospital, Ishikawa
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to examine the additional effect of fosbretabulin in com-
bination chemotherapy with paclitaxel and carboplatin,
one of the most common chemotherapeutic regimens
for ATC in Western countries [2]. Sosa et al. enrolled
80 patients with mainly stage IVC, and they described
the difficulty of enrolling patients based on their dis-
tinct eligibility criteria; they noted both the uncertainty
in pathological diagnosis and the highly aggressive
nature of ATC. They had to exclude as many as 207
patients.
In the present study, our primary endpoints were the
feasibility, safety and efficacy of the paclitaxel therapy.
Thus, we attempted to enroll as many patients as pos-
sible by constructing a system for entry based on the
database kept by a nationwide organization (the ATCCJ).
Although many patients without a target lesion might
have been enrolled, the results of this study were ex-
pected to clearly demonstrate the baseline data regard-
ing therapeutic efforts for ATC at present.
A pathological specimen from each patient is being
evaluated by the pathology review board of the ATCCJ
to confirm the pathological diagnoses of ATC. The pri-
mary endpoints of feasibility and efficacy will be evalu-
ated after the expiration of the observation period, in
April 2015. Vital information concerning additional
treatments after the protocol therapy and the causes of
death will be accumulated as well. We hope to analyze
the probability of misdiagnoses by pathology, the efficacy
of the therapy stratified by clinical staging, and the prog-
nostic index [16].
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